RTL 03 - HemOnc News: New 'gold standard' for prostate cancer screening, pandemic could increase cancer deaths, genetic testing for early cancers

Tuesday, July 28, 2020

Subscribe to Blood & Cancer: Apple Podcasts, Spotify, Google Podcasts

This week in HemOnc News:

  1. PSMA PET/CT may be new 'gold standard' for prostate cancer staging
    Source: https://bit.ly/2CRaq2t
    Study: https://bit.ly/3f18YHL
  2. Analysis of early-onset cancer suggests need for genetic testing
    Source: https://bit.ly/2WZSIR3
    AACR Abstract: https://bit.ly/3f18YHL
  3. Early screening may halve breast cancer mortality in childhood cancer survivors
    Source: https://bit.ly/2WZSIR3
    Study: https://bit.ly/39DoJUf
  4. COVID-19: Heavy toll from ongoing cancer referral delays
    Source: https://bit.ly/3g6DiSF
    First study: https://bit.ly/2WZSVnj
    Second study: https://bit.ly/30375Gp

For more MDedge Podcasts, click this link: http://bit.ly/2CfnY52

Email the show: [email protected]

Follow Dr. David Henry on Twitter @DavidHenryMD

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.